Clinical Trials Browser

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03537599 2025-05-21

Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant

Phase 1/2 Terminated

4 enrolled 7 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04435691 2025-04-27

Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia

Phase 1/2 Terminated

110 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06150040 2025-02-20

AML-NET

Phase 1/2 Terminated

1 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04029688 2024-12-20

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Phase 1/2 Terminated

38 enrolled 34 charts

CNSLymphoidOther hematologic neoplasm

Neuroblastoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02270463 2024-10-17

SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission

Phase 1/2 Terminated

16 enrolled 14 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03735875 2024-09-19

Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia

Phase 1/2 Terminated

8 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05682170 2024-09-19

Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

40 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03154827 2024-09-05

Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

1 enrolled 6 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05028751 2024-08-07

A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

24 enrolled 19 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00522990 2024-08-02

Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias

Phase 1/2 Terminated

48 enrolled

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT03176277 2024-07-15

A Study of ONO-7475 in Patients With Acute Leukemias

Phase 1/2 Terminated

42 enrolled 47 charts

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04113616 2024-03-22

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

70 enrolled

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT05345938 2024-02-23

A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia

Phase 1/2 Terminated

1 enrolled

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT04956042 2024-02-12

Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1/2 Terminated

18 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04092179 2024-01-24

ENAVEN-AML

Phase 1/2 Terminated

27 enrolled

Other hematologic neoplasm

Neoplasms, Recurrence, Leukemia, Myeloid, Acute

NCT01898793 2024-01-17

Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Phase 1/2 Terminated

89 enrolled 17 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05066165 2023-12-28

Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia

Phase 1/2 Terminated

6 enrolled 11 charts

Other hematologic neoplasm

Immune System Diseases, Immunoproliferative Disorders, Leukemia, Neoplasms, Leukemia, Myeloid, Acute

NCT02096042 2023-10-10

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

1 enrolled 3 charts

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT02743611 2023-10-05

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

Phase 1/2 Terminated

4 enrolled 9 charts

DermatologicMyeloidOther hematologic neoplasm

Uveal Melanoma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03733249 2023-09-26

Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study

Phase 1/2 Terminated

187 enrolled 8 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Primary Immunodeficiency Diseases, Cytopenia, Anemia, Anemia, Aplastic, Anemia, Sickle Cell, Fanconi Anemia, Hemoglobinopathies, Leukemia, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Thalassemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Anemia, Diamond-Blackfan, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03634228 2023-06-15

Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia

Phase 1/2 Terminated

16 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02323113 2023-02-08

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

Phase 1/2 Terminated

43 enrolled 27 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03614728 2023-02-06

Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

30 enrolled 29 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03214666 2022-11-10

GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies

Phase 1/2 Terminated

12 enrolled 20 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Mastocytosis, Systemic

NCT03760666 2022-08-08

A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1/2 Terminated

17 enrolled 14 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02773732 2022-08-05

UF-AML-CE-101

Phase 1/2 Terminated

11 enrolled 15 charts

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT01640301 2022-07-14

Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant

Phase 1/2 Terminated

47 enrolled 19 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01876953 2022-03-31

Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia

Phase 1/2 Terminated

20 enrolled 9 charts

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT04097301 2022-01-19

Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma

Phase 1/2 Terminated

8 enrolled 13 charts

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Leukemia, Myeloid, Acute

NCT02770820 2021-10-29

Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia

Phase 1/2 Terminated

9 enrolled 8 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01113502 2021-08-05

Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)

Phase 1/2 Terminated

44 enrolled 16 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02089230 2021-04-20

MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy

Phase 1/2 Terminated

19 enrolled 11 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03113071 2021-03-16

Safety and Activity of Digoxin With Decitabine in Adult AML and MDS

Phase 1/2 Terminated

1 enrolled 4 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01656252 2020-11-03

PrE0901

Phase 1/2 Terminated

15 enrolled 5 charts

Classical hematologyOther hematologic neoplasm

Jacobs syndrome, Pathologic Complete Response, Leukemia, Thrombocytopenia, Leukemia, Myeloid, Acute

NCT02953561 2020-10-22

Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

Phase 1/2 Terminated

19 enrolled 11 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Clinical Trials

NK4AML

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients

GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.

A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML

Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML

A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement

Phase l/II Study of Ruxolitinib for Acute Leukemia

Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant

Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia

AML-NET

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission

Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia

Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)

A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias

A Study of ONO-7475 in Patients With Acute Leukemias

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia

Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia

ENAVEN-AML

Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study

Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies

A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

UF-AML-CE-101

Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant

Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia

Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma

Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia

Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)

MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy

Safety and Activity of Digoxin With Decitabine in Adult AML and MDS

PrE0901

Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia